Savient Pharmaceuticals (SVNT -6%) dips after JMP Securities cuts the shares to Market...


Savient Pharmaceuticals (SVNT -6%) dips after JMP Securities cuts the shares to Market Underperform, citing limited growth potential for the company's gout treatment drug Krystexxa.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs